11-[4-(Dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 11-[4-(Dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
• 化学式: C₂₉H₃₅NO₂
• mdl: MFCD03852759
• 分子量: 429.6
• InChiKey: VKHAHZOOUSRJNA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  32
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids
  申请人：——

  公开号：US20040029846A1

  公开（公告）日：2004-02-12

  The present invention is related to novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues, their use as antiglucocorticoids for the treatment and/or prophylaxis of diseases associated to an excess of glucocorticoids. In particular, the invention relates to the use of novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues having the formula FORMULAwherein X is S, SO and SO2, and R is either M or OH, for treating Cushing's syndrome, iatrogenic hypercortisolism or depression. Also the present invention is related to methods of preparing the novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues. 1

  本发明涉及新型21-羟基-6,19-氧代孕酮（21OH-6OP）类似物，其用作抗糖皮质激素治疗和/或预防与糖皮质激素过量相关的疾病。具体来说，本发明涉及使用具有以下公式的新型21-羟基-6,19-氧代孕酮（21OH-6OP）类似物，其中X为S、SO和SO2，R为M或OH，用于治疗库欣综合征、医源性高皮质醇血症或抑郁症。此外，本发明还涉及制备新型21-羟基-6,19-氧代孕酮（21OH-6OP）类似物的方法。
• New therapeutic approaches for treating Charcot-Marie-Tooth disease
  申请人：Pharnext

  公开号：EP2065038A1

  公开（公告）日：2009-06-03

  The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders. More particularly, the invention relates to combined therapies for treating said disease by decreasing PMP22 expression in a subject.

  本发明涉及治疗夏科-玛丽-牙病及相关疾病的组合物和方法。更具体地说，本发明涉及通过降低受试者体内 PMP22 表达来治疗上述疾病的联合疗法。
• Methods of reducing incidence of stillborn pigs by using progesterone receptor antagonists
  申请人：Pfizer Inc

  公开号：US20040074447A1

  公开（公告）日：2004-04-22

  This invention provides a method for initiation of farrowing of pregnant domestic swine within a predictable number of hours by administering a progesterone receptor antagonist. The present method also significantly reduces reduce stillborn pigs. A preferred progesterone receptor antagonist for use in the present method is RU38,486. The progesterone receptor antagonist can be administered to a pregnant swine via an appropriate route of administration, such as orally, intramuscularly or intravaginally. The present invention greatly facilitates human supervision and assistance during parturition, and is important for the production and profitability of farrowing operation.

  本发明提供了一种方法，通过使用孕酮受体拮抗剂，可在可预测的小时数内使怀孕家猪开始产仔。本方法还能大大减少死胎猪。用于本方法的首选孕酮受体拮抗剂是 RU38,486。孕酮受体拮抗剂可通过适当的给药途径，如口服、肌肉注射或阴道内给药给妊娠猪。本发明极大地方便了分娩过程中的人工监护和帮助，对产仔操作的生产和盈利具有重要意义。
• SULPHUR ANALOGUES OF 21-HYDROXY-6,19-OXIDOPROGESTERONE (21OH-6OP) FOR TREATING EXCESS OF GLUCOCORTICOIDS
  申请人：Applied Research Systems ARS Holding N.V.

  公开号：EP1330468B1

  公开（公告）日：2007-08-01
• Novel use of mifepristone and derivatives therefor as hedgehog protein signaling pathway modulators and applications of same
  申请人：Ruat Martial

  公开号：US20070060546A1

  公开（公告）日：2007-03-15

  The invention relates to a novel use of compounds having formula (I), including mifepristone (RU 486 or RU 38 486) and the derivative salts thereof, for the preparation of a medicament that can modulate(activate or inhibit) the Hedgehog protein signalling pathway, which is intended for the treatment of pathologies involving a tissue dysfunction linked to deregulation of said pathway.